GPR109A/HCAR2 (extracellular) Blocking Peptide (#BLP-HR012) is the original antigen used for immunization during Anti-GPR109A/HCAR2 (extracellular) Antibody (#AHR-012) generation. The blocking peptide binds and ‘blocks’ Anti-GPR109A/HCAR2 (extracellular) primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
- Western blot analysis of rat spleen lysates (lanes 1 and 3) and rat colon membranes (lanes 2 and 4):
- Western blot analysis of mouse colon lysates (lanes 1 and 3) and mouse lung lysates (lanes 2 and 4):
- Western blot analysis of human THP-1 monocytic leukemia cell line lysates (lanes 1 and 3) and human HL-60 promyelocytic leukemia cell line lysates (lanes 2 and 4):
- Expression of GPR109A in rat cingulate cortex.Immunohistochemical staining of perfusion-fixed frozen rat brain sections with Anti-GPR109A/HCAR2 (extracellular) Antibody (#AHR-012), (1:200), followed by goat anti-rabbit-AlexaFluor-488. A. GPR109A immunoreactivity (green) appears in outlines of cortical neurons (arrows). B. Pre-incubation of the antibody with GPR109A/HCAR2 (extracellular) Blocking Peptide (BLP-HR012), suppressed staining. Cell nuclei are stained with DAPI (blue).
- Peptide (C)DNYVHNWDWRFGG, corresponding to amino acid residues 82 - 94 of mouse HCAR2 (Accession Q9EP66).